UFP Technologies reported net income of $16.4 million, or $2.11 per diluted share, for the third quarter ended September 30, 2025, matching the same period in 2024. Adjusted earnings per diluted share for the quarter were $2.39. Sales for the third quarter reached $154.6 million, up from $145.2 million in the third quarter of 2024. For the nine-month period ended September 30, 2025, net income was $50.7 million, or $6.52 per diluted share, compared to $42.6 million, or $5.49 per diluted share, in the same period of 2024. Sales for the nine-month period were $453.9 million, compared to $360.4 million a year earlier. MedTech sales increased by 7.3% in the third quarter, while non-medical business sales declined by 2.7%. Adjusted EBITDA for the third quarter was $30.7 million, down 4.9% from $32.3 million in the third quarter of 2024, while adjusted EBITDA for the nine-month period rose 20.6% to $92.8 million. The company incurred approximately $3 million in incremental labor costs at its Illinois AJR facility related to a post-acquisition review of employee work eligibility, with expectations that the impact will be significantly lower in the fourth quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UFP Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-048260), on November 03, 2025, and is solely responsible for the information contained therein.
Comments